Press releases

Oxford BioMedica to Present at 2nd Annual Regen Med Investor Day

 

Oxford, UK – 21 March 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. The event includes clinical and commercial experts who will be on-hand to address specific questions regarding the outlook for the industry, as well as offer insight into how regenerative medicine products could impact the standard of care in key therapeutic areas. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts as well as presentations by more than 30 leading companies from across the globe.

The following are specific details regarding Oxford BioMedica’s presentation:

Event: ARM’s Regen Med Investor Day

Date: March 26, 2014

Time: 2:45pm

Location: Metropolitan Club, One East 60th Street, New York, NY 10022

A live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://www.arminvestorday.com for more information.

- Ends -

Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton

Tel: +44 (0)20 3709 5700

 

Peel Hunt (Joint Corporate Brokers):

James Steel/Christopher Golden

Tel: +44 (0)20 7418 8900

 

WG Partners (Joint Corporate Brokers):

David Wilson/Claes Spang

Tel: +44 (0)20 3705 9321